Resolution of the Working Meeting of Experts in “Dermatology”: Possibilities of systemic therapy of atopic dermatitis with selective immunosuppressants

Cover Page

Cite item

Full Text

Abstract

On February 19, 2022, a working meeting of experts on the problem of atopic dermatitis was held in Moscow under the chairmanship of the Director of the State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences A.A. Kubanov. Also in attendance was the Academician of the Russian Academy of Sciences, Chief Freelance Children’s Specialist in Preventive Medicine, Head of the Research Institute of Pediatrics and Children’s Health of the Central Clinical Hospital of the Russian Academy of Sciences of the Ministry of Science, and Higher Education of the Russian Federation, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, L.S. Namazova-Baranova, and also the Deputy Director for Clinical Work ― Chief Physician of the Federal State Budgetary Institution “SSC” Institute of Immunology “FMBA of Russia” Doctor of Medical Sciences, Professor N.I. Ilyina.

The meeting raised germane issues of providing medical care, reducing the burden of the disease, and improving the quality of life of patients with atopic dermatitis. New possibilities and principles of systemic therapy in patients with moderate and severe atopic dermatitis were discussed. We analyzed data on a new representative of the small molecule class — the selective Janus kinase 1 inhibitor, upadacitinib, which was registered in the Russian Federation in June 2021. This analysis aimed to determine its place in atopic dermatitis therapy algorithms and the possibility of the impact of its use as a therapy on the quality of life of patients in relation to the burden of diseases.

The article has been published in several journals simultaneously with permission from authors and publishers. The parallel publication is available here: Capabilities of atopic dermatitis systemic therapy with selective immunosuppressors: resolution of the experts workshop of dermatology profile. Pediatric pharmacology. 2022;19(2):209–211. DOI: https://doi.org/10.15690/pf.v19i2.2424

About the authors

Andrey L. Bakulev

Central State Medical Academy of Department of Presidential Affairs

Email: al_ba05@mail.ru
ORCID iD: 0000-0002-1450-4942
SPIN-code: 6708-7386

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Elena A. Vishneva

The Russian National Research Medical University named after N.I. Pirogov; Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: vishneva.e@yandex.ru
ORCID iD: 0000-0001-7398-0562
SPIN-code: 1109-2810

MD, Dr. Sci. (Med)

Russian Federation, Moscow; Moscow

Olga G. Elisyutina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci. (Med.)

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Natalya I. Ilyina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Arfenya E. Karamova

State Scientific Center for Dermatovenereology and Cosmetology

Email: karamova@cnikvi.ru
ORCID iD: 0000-0003-3805-8489
SPIN-code: 3604-6491

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Muza M. Kokhan

Ural Research Institute for Dermatovenerology and Immunopatology

Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
SPIN-code: 3470-9306

MD, Dr. Sci (Med.), Professor

Russian Federation, Yekaterinburg

Alexey A. Kubanov

State Scientific Center for Dermatovenereology and Cosmetology

Email: alex@cnikvi.ru
ORCID iD: 0000-0002-7625-0503
SPIN-code: 8771-4990

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

Russian Federation, Moscow

Konstantin N. Monakhov

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: knmonakhov@gmail.com
ORCID iD: 0000-0002-8211-1665
SPIN-code: 1837-2098

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Leyla S. Namazova-Baranova

The Russian National Research Medical University named after N.I. Pirogov; Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531
SPIN-code: 1312-2147

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow

Gennadiy A. Novik

Saint-Petersburg State Pediatric Medical University

Email: ga_novik@mail.ru
ORCID iD: 0000-0002-7571-5460
SPIN-code: 6289-0209

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Olga Yu. Olisova

First Sechenov Moscow State Medical University (Sechenov University)

Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Vera A. Revyakina

Federal Research Center of Nutrition, Biotechnology and Food Safety

Author for correspondence.
Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927
SPIN-code: 4607-0540

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Evgeny V. Sokolovskiy

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: s40@mail.ru
ORCID iD: 0000-0001-7610-6061
SPIN-code: 6807-7137

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Elena S. Fedenko

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Marianna M. Khobeysh

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: mkhobeysh@yandex.ru
ORCID iD: 0000-0001-8670-7223
SPIN-code: 4377-8101

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, Saint Petersburg

References

  1. Clinical recommendations. Atopic dermatitis. 2021. (In Russ). Available from: https://cr.minzdrav.gov.ru. Accessed: 15.04.2022.
  2. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004
  3. Krysanov IS, Krysanova VS, Karpov OI, Ermakova VY. The economic burden of severe atopic dermatitis in the Russian Federation. Qualitative Clin Pract. 2019;(4):4–14. (In Russ). doi: 10.1016/2588-0519-2019-4-4-14
  4. Faraz A, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161. doi: 10.2340/00015555-3511
  5. Wohl Y, Wainstein J, Bar-Dayan Y. Atopic dermatitis in Israeli adolescents ― a large retrospective cohort study. Acta Derm Venereol. 2014;94(6):695–698. doi: 10.2340/00015555-1819
  6. Langenbruch A, Radtke M, Franzke N, et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol. 2014;28(6): 719–726. doi: 10.1111/jdv.12154
  7. Kurbanov AA, Bogdanova EV. Organization and results of medical care in the profile of dermatovenerology in the Russian Federation. Results of 2018. Bulletin Dermatology Venereology. 2019;95(4):8–23. (In Russ). doi: 10.25208/0042-4609-2019-95-4-8-23
  8. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. JEADV. 2018;32(5):657–682. doi: 10.1111/jdv.14891
  9. Shrestha S, Miao R, Wang L, et al. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, medicare, and medical databases. Adv Ther. 2017; 34(8):1989–2006. doi: 10.1007/s12325-017-0582-z
  10. Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018;121(5):604–612.e3. doi: 10.1016/j.anai.2018.07.042
  11. Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70(10):1300–1308. doi: 10.1111/all.12685
  12. Schmitt J, Schwarz K, Baurecht H, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137(1):130–136. doi: 10.1016/j.jaci.2015.06.029
  13. Sánchez-Pérez J, Daudén-Tello E, Mora AM, Lara Surinyac N. Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. Actas Dermosifiliogr. 2013;104(1):44–52. doi: 10.1016/j.ad.2012.03.008
  14. Narala S, Hata TR. Adult atopic dermatitis with comorbid atopic disease is associated with increased risk of infections: a population-based cross-sectional study. Dermatol Ther (Heidelb). 2017;7(1): 111–121. doi: 10.1007/s13555-017-0172-7
  15. Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19(6):821–838. doi: 10.1007/s40257-018-0383-4
  16. Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(8):2016–2020. doi: 10.1111/jocd.13263
  17. Mocanu M, Vâta D, Alexa AI, et al. Atopic dermatitis ― beyond the skin. Diagnostics. 2021;11(9):1553. doi: 10.3390/diagnostics11091553
  18. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645–1651. doi: 10.1080/03007995.2016.1195733
  19. Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40. doi: 10.1159/000381913
  20. Silverberg NB. A practical overview of pediatric atopic dermatitis, part 3: comorbidities, and measurement of disease burden. Cutis. 2016;97(6):408–412.
  21. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018;27(4):409–417. doi: 10.1111/exd.13336
  22. Darlenski R, Kazandjieva J, Hristakieva E, et al. Atopic dermatitis as a systemic disease. Clin Dermatol. 2014;32(3):409–413. doi: 10.1016/j.clindermatol.2013.11.007
  23. Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol. 2019;29(3):250–258. doi: 10.1684/ejd.2019.3557
  24. Brunner P, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25. doi: 10.1016/j.jid.2016.08.022
  25. Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892
  26. Smolkin YS, Masalsky SS, Smolkina OY. Questions of the use of biological therapy in atopic dermatitis: emphasis on dupilumab. Allergology Immunology Pediatrics. 2020;61(2):27–40. (In Russ). doi: 10.24411/2500-1175-2020-10005
  27. Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23. doi: 10.1007/s13555-016-0170-1
  28. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768
  29. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
  30. Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768–775. doi: 10.1111/bjd.15928
  31. Instructions for the medical use of the drug Mycophenolate mofetil. (In Russ). Available from: https://grls.rosminzdrav.ru/grls.aspx?s=Мофетил&m=mnn. Accessed: 15.04.2022.
  32. Instructions for the medical use of the drug Azathioprine. (In Russ). Available from: https://grls.rosminzdrav.ru/grls.aspx?s=Азатиоприн&m=mnn. Accessed: 15.04.2022.
  33. Instructions for the medical use of the drug Methotrexate. (In Russ). Available from: https://grls.rosminzdrav.ru/grls.aspx?s=Метотрексат&m=mnn. Accessed: 15.04.2022.
  34. Werfel T, Heratizadeh A, Aberer W, et al. Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges. 2021;19(1):151–168. doi: 10.1111/ddg.14371
  35. Instructions for medical use of the drug Dupixentt®. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
  36. Instructions for the medical use of the drug Olumiant®. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
  37. Instructions for the medical use of the drug SHANVAK 15 mg. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
  38. Identification of candidates for systemic therapy in clinical trials of advanced systemic methods of treatment of atopic dermatitis phase 3. (In Russ). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02277743; https://www.clinicaltrials.gov/ct2/show/NCT03349060; https://www.clinicaltrials.gov/ct2/show/NCT03435081. Accessed: 15.04.2022.
  39. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030
  40. Kok WL, Yew YW, Thng TG. Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study. Acta Derm Venereol. 2019;99(7):652–656. doi: 10.2340/00015555-3175
  41. Katayama I, Kohno Y, Akiyama K, et al. Japanese guideline for atopic dermatitis 2014. Allergol Int. 2014;63(3):377–398. doi: 10.2332/allergolint.14-RAI-0769
  42. Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol. 2016; 43(10):1117–1145. doi: 10.1111/1346-8138.13392
  43. The AAAAI offers information on Eczema (Atopic Dermatitis) symptoms, diagnosis, treatment and management. Available from: https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/eczema-(atopic-dermatitis)-overview. Accessed: 15.04.2022.
  44. Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053–1101. doi: 10.1111/1346-8138.15090
  45. Krader C, Pharm BS. Systemic Treatment for Pediatric AD. Dermatology Times. 2021;42(7).
  46. Nygaard U, Vestergaard C, Deleuran M. Systemic treatment of severe atopic dermatitis in children and adults. Current Treatment Options Allergy. 2014;1(4):1–13. doi: 10.1007/s40521-014-0032-y
  47. Instructions for the medical use of the drug Cyclosporine. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
  48. Simpson EL, Bieber T, Guttman-Yassky E, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10. 1056/NEJMoa1610020
  49. De Wijs LE, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418–426. doi: 10.1111/bjd.18179
  50. Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151. doi: 10.1016/j.jaad.2019.02.053
  51. McKenzie PL, Rangu S, Treat JR, Castelo-Soccio L. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care center: Inadequate response and adverse events. Pediatr Dermatol. 2021;38(5):1178–1184. doi: 10.1111/pde.14799
  52. Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am acad Dermatol. 2022;86(3):628–636. doi: 10.1016/j.jaad.2021.06.017
  53. Howe W. Treatment of atopic dermatitis (eczema) ― UpToDate. Last updated: Mar 11, 2022. Available from: https://www.uptodate.com/contents/treatment-of-atopic-dermatitis-eczema/print?sectionName=Frequency%20of%20bathing&search=ambulatory-&topicRef=8349&anchor=H3882190426&source=see_link. Accessed: 15.04.2022.
  54. Cartron AM, Nguyen TH, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820–824. doi: 10.1111/ced.14567
  55. Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergologie Select. 2021;5:293–304. doi: 10.5414/ALX02272E
  56. Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797–1810. doi: 10.1111/jdv.17351
  57. Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life (Basel). 2021;11(9):927. doi: 10.3390/life11090927
  58. Silverberg JI, Hong HC, Thyssen JP, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022;12(5):1181–1196. doi: 10.1007/s13555-022-00721-1
  59. Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;(2):23. doi: 10.1186/s41927-018-0031-x
  60. Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–875. doi: 10.1136/annrheumdis-2020-219012
  61. McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi: 10.1186/s13075-019-1964-1
  62. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2
  63. Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4
  64. Paller AS, Mendes-Bastos P, Eichenfield LF, et al. Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase III clinical trials. Br J Dermatol. 2021;185(3):e128–e129.
  65. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from 2 pivotal, phase 3, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2). European Academy Dermatology Venerology Congress; 2020. D3T03.4B.
  66. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2
  67. Ardern-Jones MR, Beck L, Calimlim B, et al. Rapid symptom and sleep improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis: results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up) ISAD 2021 (PE-21), Abstract from 11th George Rajka International Symposium on Atopic Dermatitis April 19–20, Korea. Seoul; 2021. P. 34.
  68. Eyerich K, Lynde CW, Calimlim B, et al. Rapid quality-of-life improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-tosevere atopic dermatitis: results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up) ISAD 2021 (PE-20), Abstract from 11th George Rajka International Symposium on Atopic Dermatitis April 19–20, Korea. Seoul; 2021. P. 34–35.
  69. Reich K, de Bruin-Weller MS, Deleuran M, et al. Eczema activity and severity index (EASI) and validated investigator global assessment of atopic dermatitis (VIGA-AD) response are associated with improvements in other outcome measures: an analysis of 3 phase 3 trials of upadacitinib in patients with moderate-to-severe atopic dermatitis, ISAD 2021 (PE-19) Abstract from 11th George Rajka International Symposium on Atopic Dermatitis April 19–20, Korea. Seoul; 2021. P. 34.
  70. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021; 157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023
  71. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi: 10.1001/jamadermatol.2022.0029
  72. Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149(3):977–987.e14. doi: 10.1016/j.jaci.2021.07.036

Copyright (c) 2022 Bakulev A.L., Vishneva E.A., Elisyutina O.G., Ilyina N.I., Karamova A.E., Kokhan M.M., Kubanov A.A., Monakhov K.N., Namazova-Baranova L.S., Novik G.A., Olisova O.Y., Revyakina V.A., Sokolovskiy E.V., Fedenko E.S., Khobeysh M.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies